Three-Year Trial on a New Testosterone Gel

NCT ID: NCT00204269

Last Updated: 2006-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-01-31

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to examine the efficacy and tolerability of a three-year-Testosterone replacement therapy in hypogonadal patients as well as the patient's compliance. The replacement therapy will be performed with a new Testosterone Gel examined in previous trials as Testosteron Gel Wolff.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the study is to examine the efficacy and tolerability of a three-year-Testosterone replacement therapy in hypogonadal patients as well as the patient's compliance. The replacement therapy will be performed with a new Testosterone Gel examined in previous trials as Testosteron Gel Wolff (TGW).

A minimum of 100 patients will be recruited and evenly distributed to two treatment arms. 1st arm: dermal (non-scrotal) application of TGW. 2nd arm: scrotal application of TGW.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypogonadism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Testosterone Gel Wolff

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

men with

* hypergonadotropic hypogonadism
* hypogonadotropic hypogonadism
* late-onset hypogonadism

combined with an initial Testosterone serum level of \< 11 nmol/l

Exclusion Criteria

* known or suspected carcinoma of the prostate
* clinically relevant abnormalities in clinical chemistry or haematology
* any severe medical conditions at the opinion of the investigator
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. August Wolff GmbH & Co. KG Arzneimittel

INDUSTRY

Sponsor Role collaborator

University Hospital Muenster

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eberhard Nieschlag, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Institute of Reproductive Medicine of the University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Clinic Charité, Division of Urology

Berlin, , Germany

Site Status

Franziskus-Hospital, Division of Urology

Bielefeld, , Germany

Site Status

University Clinic Bonn, Division of Dermatology

Bonn, , Germany

Site Status

Medical University Clinic II, Division of Internal Medicine/Andrology

Cologne, , Germany

Site Status

University Clinic Essen, Division of Internal Medicine

Essen, , Germany

Site Status

J.-W. Goethe University, Medical Clinic I, Division of Internal Medicine

Frankfurt, , Germany

Site Status

University Clinic Giessen, Division of Dermatology/Andrology

Giessen, , Germany

Site Status

University Clinic Halle Wittenberg, Division of Urology/Andrology

Halle, , Germany

Site Status

Endokrinologikum Hamburg

Hamburg, , Germany

Site Status

University Medical Clinic Hannover

Hanover, , Germany

Site Status

University Clinic Leipzig, Division of Dermatology/Andrology

Leipzig, , Germany

Site Status

Otto-von-Guerike-University, Clinic of Endocrinology

Magdeburg, , Germany

Site Status

Phillips-University-Clinic Marburg, Division of Dermatology/Andrology

Marburg, , Germany

Site Status

Insitute of Reproductive Medicine of the University

Münster, , Germany

Site Status

Private Practice of Urology

Nuremberg, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Kuhnert B, Byrne M, Simoni M, Kopcke W, Gerss J, Lemmnitz G, Nieschlag E. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol. 2005 Aug;153(2):317-26. doi: 10.1530/eje.1.01964.

Reference Type BACKGROUND
PMID: 16061839 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TGT-04/2002

Identifier Type: -

Identifier Source: secondary_id

IRM 2002/37

Identifier Type: -

Identifier Source: org_study_id